|Videos|October 3, 2022

Dr. Wee on androgen receptor inhibitors for the management of nonmetastatic CRPC

Christopher Wee, MD, discusses available androgen receptor inhibitors and unmet needs regarding the optimal use of these agents for patients with nonmetastatic castration-resistant prostate cancer.

Christopher Wee, MD, a genitourinary medical oncologist at Cleveland Clinic, discusses available androgen receptor inhibitors for the treatment of patients with nonmetastatic castration-resistant prostate cancer, including apalutamide (Erleada) darolutamide (Nubeqa) and enzalutamide (Xtandi). He also explains what is still needed to optimize the use of these agents in this space.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


Latest CME